SPY759.06+0.26%QQQ690.90+0.40%BTC/USD68,913.81−3.44%DIA523.24+0.15%GLD355.86+0.27%TLT79.57−0.19%

Anika Therapeutics Inc

ANIKNASDAQ

Trade with Public

$13.81

-0.14-1%

Last update: Nov 12, 5:45 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Earnings: Q3 2026 Earnings were released on Fri Nov 6th, before the market open

Conference Call: The most recent conference call started at 8:30 AM, 6 days ago

Click to view the webcast

Anika Therapeutics (ANIK) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Anika Therapeutics (ANIK) stock.

Analyst Consensus — 2 Analysts

2Buy

# Analysts2

Latest Upgrades and Downgrades for Anika Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	B. Riley Securities	Madison El-Saadi	Assumes	Buy	$21→$23
—	B. Riley Securities	Anderson Schock	PT Raise	Buy	$18→$21
—	Barrington Research	Michael Petusky	PT Raise	Outperform	$16→$17
—	Barrington Research	Michael Petusky	Maintained	Outperform	$16
—	Barrington Research	Michael Petusky	PT Raise	Outperform	$15→$16
—	Barrington Research	Michael Petusky	Maintained	Outperform	$15
—	Barrington Research	Michael Petusky	PT Cut	Outperform	$19→$15
—	Barrington Research	Michael Petusky	PT Cut	Outperform	$20→$19
—	Barrington Research	Michael Petusky	PT Cut	Outperform	$25→$20
—	Barrington Research	Michael Petusky	PT Cut	Outperform	$37→$25
—	Barrington Research	Michael Petusky	Maintained	Outperform	$37
—	Barrington Research	Michael Petusky	Maintained	Outperform	$37
—	Stephens & Co.	George Sellers	Maintained	Equal-Weight	$24
—	Barrington Research	Michael Petusky	Maintained	Outperform	$37
—	Stephens & Co.	George Sellers	Maintained	Equal-Weight	$22
—	Barrington Research	Michael Petusky	PT Raise	Outperform	$29→$37
—	Barrington Research	Michael Petusky	PT Raise	Outperform	$28→$29

Anika Therapeutics Inc

Anika Therapeutics (ANIK) Stock Price Target 2026

Latest Upgrades and Downgrades for Anika Therapeutics Stock

Anika Therapeutics (ANIK) Stock Price Target 2026

Latest Upgrades and Downgrades for Anika Therapeutics Stock

Analyst Ratings News

PRO
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PRO
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

People Also Watch

People Also Watch

Analyst Ratings News

PRO
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PRO
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

Anika Therapeutics Inc

Anika Therapeutics (ANIK) Stock Price Target 2026

Latest Upgrades and Downgrades for Anika Therapeutics Stock

Anika Therapeutics (ANIK) Stock Price Target 2026

Latest Upgrades and Downgrades for Anika Therapeutics Stock

Analyst Ratings News

PROB. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PROB. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PROBarrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PROBarrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PROBarrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PROBarrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

People Also Watch

People Also Watch

Analyst Ratings News

PROB. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PROB. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PROBarrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PROBarrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PROBarrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PROBarrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

PRO
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PRO
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

PRO
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PRO
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15